Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer

doi:10.3748/wjg.v22.i27.6287

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 27

This Article

(346)

(275)

(0)

(6326)

(10)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Prospective Study

World J Gastroenterol. Jul 21, 2016; 22(27): 6287-6295
Published online Jul 21, 2016. doi: 10.3748/wjg.v22.i27.6287

Full Size Figure Download Figure

Figure 3 Decrease of angiopoietin-2 in plasma in function of time. The percentage of the decrease of angiopoietin-2 (Ang-2) level in plasma as respect the baseline level (before the beginning of therapy) is reported in function of timing after therapy, before the 2^nd and the 5^th cycle.

Citation: Azzariti A, Porcelli L, Brunetti O, Del Re M, Longo V, Nardulli P, Signorile M, Xu JM, Calabrese A, Quatrale AE, Maiello E, Lorusso V, Silvestris N. Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer. World J Gastroenterol 2016; 22(27): 6287-6295
URL: https://www.wjgnet.com/1007-9327/full/v22/i27/6287.htm
DOI: https://dx.doi.org/10.3748/wjg.v22.i27.6287

Azzariti A, Porcelli L, Brunetti O, Del Re M, Longo V, Nardulli P, Signorile M, Xu JM, Calabrese A, Quatrale AE, Maiello E, Lorusso V, Silvestris N. Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer. World J Gastroenterol 2016; 22(27): 6287-6295 [PMID: 27468218 DOI: 10.3748/wjg.v22.i27.6287]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.